Who are SAMe's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ademetionine IV+tablet, Tucidinostat, Azacitidine combined with CHOP, Methylcobalamin (methylB12), D-138, Methyl B12, Mecobalamin IM injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/same.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

SAMe — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SAMe (SAMe) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin B12 [EPC]. Area: Metabolic.

marketed Vitamin B12 [EPC] Methyltransferases Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

SAMe (SAMe) — Mclean Hospital.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SAMe TARGET	SAMe	Mclean Hospital	marketed	Vitamin B12 [EPC]	Methyltransferases
Ademetionine IV+tablet	Ademetionine IV+tablet	Abbott	phase 3	Methyl donor / Hepatoprotective agent	S-adenosylmethionine synthetase substrate; indirect effects on methyltransferases and glutathione synthesis
Tucidinostat, Azacitidine combined with CHOP	Tucidinostat, Azacitidine combined with CHOP	Peking Union Medical College Hospital	phase 3	Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen	Histone deacetylases, DNA methyltransferases
Methylcobalamin (methylB12)	Methylcobalamin (methylB12)	Arkansas Children's Hospital Research Institute	marketed	Vitamin B12 supplement / Cobalamin	Methionine synthase; methylmalonyl-CoA mutase cofactor
D-138	CHOLESTEROL	DNA Labs, Inc.	marketed	Vitamin B12 [EPC]
Methyl B12	Methyl B12	University of California, San Francisco	marketed	Vitamin B12 supplement	Methionine synthase
Mecobalamin IM injection	Mecobalamin IM injection	Eisai Co., Ltd.	marketed	Vitamin B12 analog	Methionine synthase; B12-dependent enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin B12 [EPC] class)

DNA Labs, Inc. · 1 drug in this class
Mclean Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SAMe — Competitive Intelligence Brief. https://druglandscape.com/ci/same. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing